The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL

OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity				
	Previous			
CIK (Filer ID Number)	Names	X None	Entity Type	
0001878313			X Corporation	
Name of Issuer			Limited Partnership	
MAIA Biotechnology, Inc.			Limited Liability Company	
Jurisdiction of Incorporation/Org	ganization		吕	
DELAWARE			☐ General Partnership	
Year of Incorporation/Organizat	ion		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Spe	cify Year)			
Yet to Be Formed				
2. Principal Place of Business	and Contact Information			
Name of Issuer				
MAIA Biotechnology, Inc.				
Street Address 1		Street Address 2		
444 West Lake Street		Suite 1700		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
Chicago	ILLINOIS	60606	312-416-8592	
3. Related Persons				
Last Name	First Name		Middle Name	
Vitoc	Vlad			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Cou	ntry	ZIP/PostalCode	
Chicago	ILLINOIS		60606	
Relationship: X Executive Office	er X Director Promoter			
Clarification of Response (if Neo	cessary):			
Chief Executive Officer, President	and Chairman of the Board of Directors			
Last Name	First Name		Middle Name	
Himmelreich	Jeffrey			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Cou	ntry	ZIP/PostalCode	
Chicago	ILLINOIS		60606	
Relationship: X Executive Office				
Clarification of Response (if Neo	cessary):			
Head of Finance				
Last Name	First Name		Middle Name	
Gryaznov	Sergei			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700		71D/D4-1Cd	
City	State/Province/Cou	ntry	ZIP/PostalCode	
Chicago	ILLINOIS		60606	

Relationship: X Executive Officer Director Promoter				
Clarification of Response (if Necessary):				
Chief Scientific Officer				
Last Name	First Name	Middle Name		
Theagene	Jean-Manasse			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
	Promoter			
Clarification of Response (if Necessary):				
Last Name	First Name	Middle Name		
Chaouki	Steven			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
		00000		
Relationship: Executive Officer X Director I	Promoter			
Clarification of Response (if Necessary):				
Last Name	First Name	Middle Name		
Smith	Stan	V.		
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
Relationship: Executive Officer X Director I				
Clarification of Response (if Necessary):				
LadNaga	FortNess	Middle Mana		
Last Name	First Name	Middle Name		
Guerrero	Ramiro			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
Relationship: Executive Officer X Director I	Promoter			
Clarification of Response (if Necessary):				
Last Name	First Name	Middle Name		
Louie	Ngar Yee			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
Relationship: Executive Officer X Director I				
Clarification of Response (if Necessary):				
Last Name	First Name	Middle Name		
Luput	Cristian			
Street Address 1	Street Address 2			
444 West Lake Street	Suite 1700			
City	State/Province/Country	ZIP/PostalCode		
Chicago	ILLINOIS	60606		
	romoter			
Clarification of Response (if Necessary):				

4. Industry Group		
Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No	Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial	Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions
Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Construction REITS & Finance Residential Other Real Estate	☐ Other Travel ☐ Other ☐ Other
5. Issuer Size		
Revenue Range OR No Revenues \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s)	No Aggregat \$1 - \$5,000,0 \$5,000,001 \$25,000,001 \$50,000,001 Over \$100,00 Decline to Di Not Applicab	\$25,000,000 - \$50,000,000 - \$100,000,000 00,000 sclose
o. Federal Exemption(s) and Exclusion(s)	Ciaimed (Select all that appl	<u>y) </u>
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Investment Section 3	(c)(2) Section 3(c)(10) (c)(3) Section 3(c)(11) (c)(4) Section 3(c)(12) (c)(5) Section 3(c)(13) (c)(6) Section 3(c)(14)
7 7		
7. Type of Filing X New Notice Date of First Sale 2024-03-1 Amendment 8. Duration of Offering	1 First Sale Yet to Occur	
o. Duration of Offering		
Does the Issuer intend this offering to last m	nore than one year?	No

9. Type(s) of Securities Offered (select all that apply)				
X Equity	Pooled Investment Fund Interests			
Debt	Tenant-in-Common Securities			
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities			
Security to be Acquired Upon Exercise of Option, Warrant or Other Rig	ght to Other (describe)			
Acquire Security				
10. Business Combination Transaction				
Is this offering being made in connection with a business combination transexchange offer?	nsaction, such as a merger, acquisition or $\ \ \ \ \ \ \ \ \ \ \ \ \ $			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor \$0 USD				
12. Sales Compensation				
Recipient	Recipient CRD Number X None	cipient CRD Number X None		
(Associated) Broker or Dealer \overline{X} None	(Associated) Broker or Dealer CRD Number $\overline{\mathbb{X}}$ None			
Street Address 1	Street Address 2			
City State(s) of Solicitation (select all that apply)	State/Province/Country	ZIP/Postal Code		
Check "All States" or check individual States	Foreign/non-US			
13. Offering and Sales Amounts				
Total Offering Amount \$5,700,000 USD or Indefinite				
Total Amount Sold \$2,920,692 USD				
Total Remaining to be Sold \$2,779,308 USD or Indefinite				
Clarification of Response (if Necessary):				
14. Investors				
Select if securities in the offering have been or may be sold to person:	s who do not qualify as accredited investors, and enter the number of	.f		
such non-accredited investors who already have invested in the offering		· 		
Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	sold to persons who do not qualify as accredited investors, enter the	19		
15. Sales Commissions & Finder's Fees Expenses				
·	reason if any lifthe amount of an averagity is not known around	an actimate and		
Provide separately the amounts of sales commissions and finders fees ex check the box next to the amount.	cpenses, if any. If the amount of an expenditure is not known, provide	an estimate and		
Sales Commissions \$0 USD Estimate				
Finders' Fees \$0 USD Estimate				
Clarification of Response (if Necessary):				
16. Use of Proceeds				
Provide the amount of the gross proceeds of the offering that has been or	is proposed to be used for payments to any of the persons required	to be named as		
executive officers, directors or promoters in response to Item 3 above. If the	he amount is unknown, provide an estimate and check the box next t	to the amount.		
\$0 USD ☐ Estimate				
Clarification of Response (if Necessary):				
Signature and Submission				
Please verify the information you have entered and review the Terms	s of Submission below before signing and clicking SUBMIT belo	w to file this notice.		
Terms of Submission				

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one
 of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
MAIA Biotechnology, Inc.	/s/ Vlad Vitoc	Vlad Vitoc	Chief Executive Officer	2024-03-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials under this undertaking or otherwise and can require offering materials under this undertaking or otherwise and can require offering materials under this undertaking or otherwise and can require offering materials under this undertaking or otherwise and can require offering materials under the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials under the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of the States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of this Form D, States are subject to the subject of the subject to the subject t